跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CD19 targeted CAR-T
首页
药物
CD19 targeted CAR-T
CD19 targeted CAR-T
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
ANTIGEN SPECIFIC CD19-TARGETED CAR-T CELLS
EP 3962955 A4
申请人: ATARA BIOTHERAPEUTICS INC
优先权: 2019
EP
US
2 件公开
TREATMENT METHODS FOR SECOND LINE THERAPY OF CD19-TARGETED CAR T CELLS
US 20250381272 A1
申请人: JUNO THERAPEUTICS INC
优先权: 2022
CN
US
2 件公开
CD19-TARGETED CAR T CELL THERAPY
EP 4754264 A1
申请人: PRECIGEN INC
优先权: 2023
EP
WO
2 件公开
CIRCULAR RNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TARGETED DELIVERY
US 20260250349 A1
申请人: ORBITAL THERAPEUTICS INC
优先权: 2025
US
WO
2 件公开
Fusion protein for reversing tumor microenvironment and application thereof
CN 117844761 A
申请人: CHONGQING PREC BIOTECH CO LTD
优先权: 2020
CN
2 件公开
Preparation method and application of autologous CAR (chimeric antigen receptor)-T cell
CN 106755088 A
申请人: GUANGDONG PANGUARD CELL BIOLOGICAL TECH CO LTD
优先权: 2016
CN
CD19 targeted CAR (chimeric antigen receptor)-T cell, preparation method and application
CN 107287164 A
申请人: QINGDAO XIEHE HUAMEI MEDICAL DIAGNOSIS TECH CO LTD
优先权: 2017
CN
Research method for targeted therapy of hematological malignant tumors
CN 111197060 A
申请人: SHANGHAI HRAIN BIOTECHNOLOGY CO LTD
优先权: 2018
CN
Double chimeric antigen receptor gene-modified immune cell based on CD19 and BCMA and application thereof
CN 109468283 A
申请人: BEIJING MEIKANG JIMIAN BIOTECHNOLOGY CO LTD
优先权: 2018
CN
Double chimeric antigen receptor gene-modified immune cell based on CD19 and PSMA and application thereof
CN 109468284 A
申请人: BEIJING MEIKANG JIMIAN BIOTECHNOLOGY CO LTD
优先权: 2018
CN
第 1 / 4 页
上一页
下一页
药物
反馈